Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

IVUS in Unprotected LMCA Angioplasty: Should We Change the Way We Use It?

Courtesy of Dr. Carlos Fava.

Bifurcation lesions account for about 25% of all angioplasties and it is a challenge for which there is no single treatment strategy.

La era del stent provisional para las bifurcaciones parece llegar a su fin

Intravascular ultrasound (IVUS) has proven its usefulness, improving outcomes by reducing mortality in unprotected left main coronary artery (LMCA) angioplasty.

A new strategy consists in conducting an IVUS after pre-dilation, after stent implantation, and post-dilation. However, such alternative has not been validated yet.

Researchers analyzed 9525 patients from the IRIS-DES registry with severe left main coronary artery, bifurcation, long or diffuse (>30 mm), or severely calcified lesions controlled through IVUS. Among them, 3374 (35.4%) patients underwent endoluminal ultrasound at pre-dilation, after stent implantation, and post-dilation (iPSP).


Read also: Detection of Late Complications After EVAR.


The primary endpoint at follow-up was cardiac death, target-vessel infarction, and target-vessel revascularization (TVR).

Patients who underwent iPSP angioplasty were younger and mostly male, had more risk factors, bifurcation lesions, severe calcification, longer lesions, and more stents. Consequently, researchers used propensity score matching to adjust populations and reach uniformity, leaving 3130 patients in each group.

The follow-up went on for 3 years and the primary endpoint favored iPSP patients (5.6% vs. 7.9%; adjusted hazard ratio [HR]: 0.71; 95% confidence interval [CI]: 0.63 to 0.81; p < 0.001).


Read also: EuroPCR 2020 | Aortic Valve in Valve in the Long Term.


Analyzing the secondary endpoints, iPSP was associated with lower mortality (2.2% vs. 3.4%; adjusted HR: 0.62; 95% CI: 0.51 to 0.75; p 0.003) and TVR (3.4% vs. 4.6%; adjusted HR: 0.74; 95% CI: 0.63 to 0.87; p < 0.001), and there were no differences as regards infarction (0.3% vs. 0.5%; adjusted HR: 0.65; 95% CI: 0.38 to 1.10; p = 0.10).

Conclusion

In patients who underwent complex unprotected left main coronary artery angioplasty with drug-eluting stents (DES), iPSP was associated with a lower risk of cardiac events after 3 years of follow-up.

Consequently, iPSP should be used more proactively in complex coronary angioplasties nowadays.

Courtesy of Dr. Carlos Fava.

Título Original: Optimal Stenting Technique for Complex Coronary Lesions Intracoronary Imaging-Guided Pre-Dilation, Stent Sizing, and Post-Dilation.

Referencia: Hanbit Park, el al. J AmColl Cardiol Intv 2020;13:1403–13.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...